109th CONGRESS
1st Session
S. 1930
To expand the research, prevention, and awareness activities of the
National Institute of Diabetes and Digestive and Kidney Diseases and the Centers
for Disease Control and Prevention with respect to inflammatory bowel disease.
IN THE SENATE OF THE UNITED STATES
October 27, 2005
Mr. REID (for himself and Mr. COCHRAN) introduced the following bill;
which was read twice and referred to the Committee on Health, Education, Labor,
and Pensions
A BILL
To expand the research, prevention, and awareness activities of the
National Institute of Diabetes and Digestive and Kidney Diseases and the Centers
for Disease Control and Prevention with respect to inflammatory bowel disease.
Be it enacted by the Senate and House of Representatives of the United
States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the `Inflammatory Bowel Disease Research Act'.
SEC. 2. FINDINGS.
The Congress finds as follows:
(1) Crohn's disease and ulcerative colitis are serious inflammatory diseases
of the gastrointestinal tract.
(2) Crohn's disease may occur in any section of the gastrointestinal tract
but is predominately found in the lower part of the small intestine and
the large intestine. Ulcerative colitis is characterized by inflammation
and ulceration of the innermost lining of the colon. Complete removal of
the colon in patients with ulcerative colitis can potentially alleviate
and cure symptoms.
(3) Because Crohn's disease and ulcerative colitis behave similarly, they
are collectively known as inflammatory bowel disease. Both diseases present
a variety of symptoms, including severe diarrhea; abdominal pain with cramps;
fever; and rectal bleeding. There is no known cause of inflammatory bowel
disease, or medical cure.
(4) It is estimated that up to 1,400,000 people in the United States suffer
from inflammatory bowel disease, 30 percent of whom are diagnosed during
their childhood years.
(5) Children with inflammatory bowel disease miss school activities because
of bloody diarrhea and abdominal pain, and many adults who had onset of
inflammatory bowel disease as children had delayed puberty and impaired
growth and have never reached their full genetic growth potential.
(6) Inflammatory bowel disease patients are at high risk for developing
colorectal cancer.
(7) The total annual medical costs for inflammatory bowel disease patients
is estimated at more than $2,000,000,000.
SEC. 3. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES;
INFLAMMATORY BOWEL DISEASE RESEARCH EXPANSION.
(a) In General- The Director of the National Institute of Diabetes and Digestive
and Kidney Diseases shall expand, intensify, and coordinate the activities
of the Institute with respect to research on inflammatory bowel disease, with
particular emphasis on the following areas:
(1) Genetic research on susceptibility for inflammatory bowel disease, including
the interaction of genetic and environmental factors in the development
of the disease.
(2) Research targeted to increase knowledge about the causes and complications
of inflammatory bowel disease in children.
(3) Animal model research on inflammatory bowel disease, including genetics
in animals.
(4) Clinical inflammatory bowel disease research, including clinical studies
and treatment trials.
(5) Expansion of the Institute's Inflammatory Bowel Disease Centers program
with a focus on pediatric research.
(6) Other research initiatives identified by the scientific document entitled
`Challenges in Inflammatory Bowel Disease' and the research agenda for pediatric
gastroenterology, hepatology and nutrition entitled `Chronic Inflammatory
Bowel Disease'.
(b) Authorization of Appropriations-
(1) IN GENERAL- For the purpose of carrying out subsection (a), there are
authorized to be appropriated $75,000,000 for fiscal year 2006, $85,000,000
for fiscal year 2007, and $100,000,000 for fiscal year 2008.
(2) RESERVATION- Of the amounts authorized to be appropriated under paragraph
(1), not more than 20 percent shall be reserved for the training of qualified
health professionals in biomedical research focused on inflammatory bowel
disease, including pediatric investigators.
SEC. 4. CENTERS FOR DISEASE CONTROL AND PREVENTION; NATIONAL INFLAMMATORY
BOWEL DISEASE ACTION PLAN.
(1) PREPARATION OF PLAN- The Director of the Centers for Disease Control
and Prevention, in consultation with the inflammatory bowel disease community,
shall prepare a comprehensive plan to address the burden of inflammatory
bowel disease in both adult and pediatric populations (which plan shall
be designated by the Director as the `National Inflammatory Bowel Disease
Action Plan').
(2) REPORT TO CONGRESS- Not later than 12 months after the date of the enactment
of this Act, the Director of the Centers for Disease Control and Prevention
shall submit the Plan referred to in paragraph (1) to the Committee on Energy
and Commerce and the Committee on Appropriations in the House of Representatives
and to the Committee on Health, Education, Labor and Pensions and the Committee
on Appropriations in the Senate.
(1) IN GENERAL- The National Inflammatory Bowel Disease Action Plan shall
address strategies for determining the true prevalence of inflammatory bowel
disease in the United States, and the unique demographic characteristics
of the patient community through the expansion of appropriate epidemiological
activities.
(2) CERTAIN REQUIREMENTS- The Plan referred to in paragraph (1) shall--
(A) focus on strategies for increasing awareness about inflammatory bowel
disease within the general public and the health care community in order
to facilitate more timely and accurate diagnoses; and
(B) address mechanisms designed to prevent the progression of the disease
and the development of complications, such as colorectal cancer, and other
strategies and activities as deemed appropriate.
(c) Authorization of Appropriations- For the purpose of carrying out this
section, there is authorized to be appropriated such sums as may be necessary
for fiscal year 2006.
END
